Skip to content
Review Open access

Developments in human papillomavirus vaccines, schedules, and implementation strategies.

Aug 2026 · Journal of the National Cancer Institute. Monographs · Vol 2026 73, pp. 137-147 · 0 citations
Medicine

TL;DR

Broad implementation of primary HPV-based screening, including self-sampling, will improve cervical cancer prevention and inform many more women of their high-risk HPV-positive status, and development of high-risk HPV-targeted therapeutics could further accelerate declines in cervical cancer by clearing prevalent infections.

Read PDF

Similar papers

Review Open access Sep 2026

Human Papillomavirus (HPV) Vaccination and the Impact of Vaccine Implementation in Kenya: Progress, Challenges, and Future Directions

Human papillomavirus (HPV) is the primary etiological agent of cervical cancer, a disease that remains a major cause of cancer-related morbidity and mortality among women in Kenya despite the availability of highly effective prophylactic vaccines. This review examines the current evidence on HPV virology, vaccine immun...

Maru Adams, Lelei Walter, Zefaniah Katuah et al. · 0 citations
Open access Sep 2026

Variation in HPV Vaccination Coverage Across the European Union

The current structural, cultural, and programmatic determinants of HPV vaccination differences across EU member states are investigated to investigate vaccine hesitancy, cervical cancer prevalence, immigration, single-dose regimen adoption, parent support, physician recommendation practices, and school-based vaccinatio...

L. Dupont, J. Jackson · 0 citations
Review Open access Aug 2026

HUMAN PAPILLOMAVIRUS (HPV): CURRENT STRATEGIES FOR THE PREVENTION AND TREATMENT OF PRECANCEROUS LESIONS

Background: Human papillomavirus (HPV) infection is the primary etiology of cervical cancer and its immediate precursors, collectively known as cervical intraepithelial neoplasia (CIN). Although primary prevention via prophylactic vaccination and secondary screening have significantly reduced incidence, cervical cancer...

Wiktor Śliwiński, Jakub Mazur, M. Kosowski et al. · 0 citations
Review Open access Sep 2026

Elimination of HPV-associated cancers: universal HPV vaccination and the role of anal screening – a meeting report

The HPV Prevention and Control Board convened its 18th technical meeting in Antwerp, Belgium (June 2025) to review the evidence on universal HPV vaccination and the role of anal cancer screening in the elimination of HPV-associated cancers. While HPV prevention has historically focused on cervical cancer in women, grow...

F. R. Burdier, L. Bruni, Anna R. Giuliano et al. · 0 citations
Review Open access Sep 2026

Human Papillomavirus Vaccination as the Basis for Cervical Cancer Prevention: Current Status and Prospects in the Kyrgyz Republic

Human papillomavirus (HPV) is the primary etiological factor responsible for the development of cervical cancer and several other anogenital malignancies. According to the World Health Organization, more than 95% of cervical cancer cases are associated with persistent infection caused by high-risk HPV types. Currently,...

A. Amanbekov, Z. Kurmanalieva, C. Stakeeva et al. · 0 citations
Open access Sep 2026

Off-Label HPV Vaccination in a 67-Year-Old Woman with Recurrent HPV Infection

Human Papillomavirus (HPV) is a highly prevalent sexually transmitted infection associated with malignancies of the cervix, vulva, and vagina. While prophylactic vaccination with Gardasil®9 is FDA-approved through age 45, no clinical trials have evaluated its use in older adults who remain sexually active and at risk f...

Rachel Michel, Caitlin S. Stukel, M. Pearl et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.